Skip to main content
GMAB
NASDAQ Life Sciences

Epcoritamab Monotherapy Achieves 67% ORR in Elderly DLBCL, Genmab Reports

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$25.08
Mkt Cap
$14.936B
52W Low
$20.225
52W High
$35.43
52W Position info
24% above low
Off High info
29% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

GMAB sits 24% above its 52-week low of $20.225.

Summary

Genmab reported strong clinical trial results for its drug epcoritamab in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Monotherapy achieved a 67% overall response rate (ORR) and 58% complete response (CR), while a combination regimen showed a 93% ORR and 86% CR. These high response rates are particularly significant for a patient population with limited treatment options and high unmet medical need. The data was presented at a major medical conference and published in The Lancet Haematology, underscoring its importance for Genmab's pipeline.

At the time of this announcement, GMAB was trading at $25.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.9B. The 52-week trading range was $20.23 to $35.43. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

GMAB - Latest Insights

GMAB
Nov 05, 2026, 11:04 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $54.17
Real-time Price: $51.30 info
Change: -$2.87 (-5%) info
Market Cap: $30.674B info
GMAB
Oct 28, 2026, 9:41 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $45.12
Real-time Price: $51.30 info
Change: +$6.18 (+14%) info
Market Cap: $30.674B info
GMAB
Oct 26, 2026, 11:08 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $44.35
Real-time Price: $51.30 info
Change: +$6.95 (+16%) info
Market Cap: $30.674B info
GMAB
Oct 26, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $45.35
Real-time Price: $51.30 info
Change: +$5.95 (+13%) info
Market Cap: $30.674B info
GMAB
Oct 23, 2026, 11:56 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $40.64
Real-time Price: $51.30 info
Change: +$10.66 (+26%) info
Market Cap: $30.674B info